Soleno Therapeutics Inc (SLNO)
NASDAQ:SLNO
Want to see SLNO full AI Analyst Report?
SLNO Stock Chart & Stats
$52.57
-$1.55(-3.35%)
At close: 4:00 PM EST
$52.57
-$1.55(-3.35%)
Day’s Range― - ―
52-Week Range$29.43 - $90.32
Previous CloseN/A
Volume118.06K
Average Volume (3M)4.89M
Market Cap
$2.71B
Enterprise Value$2.65B
Total Cash (Recent Filing)$305.47M
Total Debt (Recent Filing)$2.69M
Price to Earnings (P/E)117.9
Beta0.93
Next Earnings
May 12, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding51,624,386
10 Day Avg. Volume11,346,460
30 Day Avg. Volume4,886,265
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)5.47
Price to Sales (P/S)12.93
P/FCF Ratio52.69
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue13.93
Enterprise Value/Gross Profit14.13
Enterprise Value/Ebitda93.42
Forecast
1Y Price Target
$65.50Price Target Upside24.60% Upside
Rating ConsensusHold
Number of Analyst Covering13
EPS Forecast (FY)3.97
Revenue Forecast (FY)$467.14M
Bulls Say, Bears Say
Bulls Say
Acquisition Certainty And FundingA definitive cash acquisition agreement funded from the buyer's cash on hand provides clear, guaranteed value for shareholders and eliminates financing risk around the transaction.
Commercial Traction And Payer SupportStrong early U.S. launch with rapidly increasing patient starts, expanding prescriber engagement, and growing Medicaid coverage indicates meaningful commercial momentum that can drive revenue growth.
Intellectual Property And ExclusivityExpectations of longer patent protection for the lead product could extend market exclusivity and enhance long‑term revenue visibility.
Bears Say
Deal Valuation And Limited UpsideA modest acquisition premium combined with limited competing bidders and analysts aligning targets to the deal constrains potential upside for remaining shareholders.
Reduced International OpportunityWithdrawal or exclusion of the European filing limits international commercialization prospects and removes a potential source of incremental revenue outside the United States.
Safety And Tolerability ConcernsReports of pulmonary and cardiac safety issues and elevated treatment discontinuation rates pose material adoption risk and could prompt heightened regulatory or provider caution.
Soleno Therapeutics News
SLNO FAQ
What was Soleno Therapeutics Inc’s price range in the past 12 months?
Soleno Therapeutics Inc lowest stock price was $29.43 and its highest was $90.32 in the past 12 months.
What is Soleno Therapeutics Inc’s market cap?
Soleno Therapeutics Inc’s market cap is $2.71B.
When is Soleno Therapeutics Inc’s upcoming earnings report date?
Soleno Therapeutics Inc’s upcoming earnings report date is May 12, 2026 which is in 25 days.
How were Soleno Therapeutics Inc’s earnings last quarter?
Soleno Therapeutics Inc released its earnings results on Feb 25, 2026. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.711 by $0.089.
Is Soleno Therapeutics Inc overvalued?
According to Wall Street analysts Soleno Therapeutics Inc’s price is currently Undervalued.
Does Soleno Therapeutics Inc pay dividends?
Soleno Therapeutics Inc does not currently pay dividends.
What is Soleno Therapeutics Inc’s EPS estimate?
Soleno Therapeutics Inc’s EPS estimate is 0.68.
How many shares outstanding does Soleno Therapeutics Inc have?
Soleno Therapeutics Inc has 51,624,386 shares outstanding.
What happened to Soleno Therapeutics Inc’s price movement after its last earnings report?
Soleno Therapeutics Inc reported an EPS of $0.8 in its last earnings report, beating expectations of $0.711. Following the earnings report the stock price went down -7.12%.
Which hedge fund is a major shareholder of Soleno Therapeutics Inc?
Currently, no hedge funds are holding shares in SLNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Soleno Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$65.50 (24.60% Upside)
$65.50 (24.60% Upside)
Blogger Sentiment
Bearish
SLNO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 773.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $429.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.16%
12-Months-Change
Fundamentals
Return on Equity
5.90%
Trailing 12-Months
Asset Growth
70.36%
Trailing 12-Months
Company Description
Soleno Therapeutics Inc
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
SLNO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong commercial launch and material financial progress — meaningful sequential revenue growth (~40% Q/Q), positive operating cash flow and full-year profitability — alongside encouraging commercial metrics (1,250 start forms, 859 active patients, 630 prescribers and coverage of >180M lives). Key near-term risks flagged include EU regulatory uncertainty, anticipated increases in COGS as inventory normalizes, seasonality-driven Q1 gross-to-net effects, elevated SG&A for continued launch investment, and an expected long-term discontinuation range of 15%–20%. On balance, the positive financial and commercial momentum and ample cash runway outweigh the outlined challenges.View all SLNO earnings summariesSLNO Stock 12 Month Forecast
Average Price Target
$65.50
▲(24.60% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---